Cogora: The Agency – August digest
August has certainly not witnessed a sleepy summer slow-down in activity from the Cogora: The Agency team!
A big push is on to deliver a complex and engagingly ambitious programme of educational and logistical support for a workstream informing care pathway enhancements is atopic dermatitis and alopecia areata. Culminating in publication of a peer-reviewed manuscript in a Medline-cited journal, the process is calling on our expertise and experience in executing landscape analyses, Delphi process-driven consensus and convening of expert advisory boards.
Prostate cancer is the second most frequently diagnosed cancer, and the fifth leading cause of cancer death in men. Every year, over 2 million men worldwide will undergo a prostate biopsy, with transperineal prostate ultrasound-guided biopsy having distinct clinical benefits over alternative techniques. Cogora: The Agency is busily executing its role as Secretariat for the collation and analysis of UK data on patient and clinician experience and on quality of core sampling, to culminate in an advisory board and Medline-cited publication at the end of the month.
Cogora: The Agency continues to make an impact on the world of vascular access management, with the 9th meeting of a clinical advisory board yielding a selection of future projects, including a pan-EU guideline for the management of peripheral vascular access devices, the collection of real-world data of vascular access complications and the creation of modules for an EU vascular access curriculum. The Agency will be participating in these initiatives, for which the month of August has been instrumental in laying the groundwork, so watch this space.
These innovative and truly exciting initiatives are in addition to the ongoing projects cited in recent newsletters.
Check out what the team were up to in July for more examples of how Cogora: The Agency, a leading Healthcare Professional Communications Agency, delivers consistent value for its clients. For more information, please contact us.